ArticleFrontiers in public health2025
Sex differences in ischemic heart disease and evidence gathering related to exposure risk, prevention, and treatment of per- and poly-fluoroalkyl substances.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the sex differences in environmental exposure to per- and poly-fluoroalkyl substances (PFAS) in ischemic heart disease (IHD) and to identify potential targets for future prevention and treatment of PFAS-associated IHD. Methods: The Global Health Data Exchange database was used to explore the sex differences in IHD mortality and morbidity. The National Health and Nutrition Examination Survey (NHANES) database was used to identify sex differences in response to environmental exposure to PFAS, including survival probability and dose-response. The Comparative Toxicogenomics Database and Gene Expression Omnibus databases were used to search for critical signaling pathways involved in IHD pathogenesis and potential targets for the prevention and treatment of PFAS-associated IHD. The binding stability of these complexes was evaluated by molecular docking and molecular dynamics simulations. Results: Globally, the mortality, morbidity, years of life lost, and years lived with disability are higher for men than women. Among 42,742 participants from NHANES, including IHD and control groups as well as PFAS-affected IHD subjects, men had significantly lower survival rates than women. Four PFAS exposures, including perfluorooctane sulfonamide, perfluorooctane sulfonic acid (PFOS), perfluorooctanoic acid (PFOA), and 2-(N-methyl-PFOSA) acetate, significantly worsened the survival of patients with IHD and interacted with 105 human genes associated with cardiovascular diseases. Combining differentially expressed genes from the pluripotent stem cell-derived cardiomyocyte dataset, five promising genes-CASP3, PDK4, GDF15, RPL17, and CTNNB1-were identified as having high binding stability to PFAS. Conclusion: Men with IHD have significantly worse survival rates than women, yet women are more susceptible to PFOA and PFOS toxicity. This study also identifies several PFAS receptor genes that affect key pathways in IHD pathogenesis, which are promising potential targets for future prevention and treatment of PFAS-associated IHD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.